» Articles » PMID: 36701109

Toll-Like Receptor 4 Plays a Significant Role in the Biochemical and Neurological Alterations Observed in Two Distinct Mice Models of Huntington's Disease

Overview
Journal Mol Neurobiol
Date 2023 Jan 26
PMID 36701109
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptors (TLRs) are central players in innate immunity responses. They are expressed in glial cells and neurons, and their overactivation leads to the production of proinflammatory molecules, neuroinflammation, and neural damage associated with many neurodegenerative pathologies, such as Huntington's disease (HD). HD is an inherited disorder caused by a mutation in the gene coding for the protein Huntingtin (Htt). Expression of mutated Htt (mHtt) causes progressive neuronal degeneration characterized by striatal loss of GABAergic neurons, oxidative damage, neuroinflammatory processes, and impaired motor behavior. The main animal models to study HD are the intrastriatal injection of quinolinic acid (QA) and the transgenic B6CBA-Tg (HDexon1)61Gpb/1 J mice (R6/1). Those models mimic neuronal damage and systemic manifestations of HD. The objective of this work was to study the participation of TLR4 in the manifestations of neuronal damage and HD symptoms in the two mentioned models. For this purpose, C57BL6/J and TLR4-KO mice were administered with QA, and after that motor activity, and neuronal and oxidative damages were measured. R6/1 and TLR4-KO were mated to study the effect of low expression of TLR4 on the phenotype manifestation in R6/1 mice. We found that TLR4 is involved in motor activity, and neurological and oxidative damage induced by intrastriatal injection of QA, and the low expression of TLR4 causes a delay in the onset of phenotypic manifestations by the mHtt expression in R6/1 mice. Our results show that TLR4 is involved in both models of HD and focuses then as a therapeutic target for some deleterious reactions in HD.

Citing Articles

Immune signature of gene expression pattern shared by autism spectrum disorder and Huntington's disease.

Liu H, Bai Q, Wang X, Jin Y, Ju X, Lu C IBRO Neurosci Rep. 2024; 17:311-319.

PMID: 39398347 PMC: 11471255. DOI: 10.1016/j.ibneur.2024.09.004.


Gut Microbiota as a Modifier of Huntington's Disease Pathogenesis.

Khoshnan A J Huntingtons Dis. 2024; 13(2):133-147.

PMID: 38728199 PMC: 11307070. DOI: 10.3233/JHD-240012.

References
1.
Shelbourne P, Keller-McGandy C, Bi W, Yoon S, Dubeau L, Veitch N . Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet. 2007; 16(10):1133-42. DOI: 10.1093/hmg/ddm054. View

2.
Barry J, Bui M, Levine M, Cepeda C . Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway. Neurobiol Dis. 2021; 162:105574. PMC: 9328779. DOI: 10.1016/j.nbd.2021.105574. View

3.
Lago T, Davis A, Grillon C, Ernst M . Striatum on the anxiety map: Small detours into adolescence. Brain Res. 2016; 1654(Pt B):177-184. PMC: 5140771. DOI: 10.1016/j.brainres.2016.06.006. View

4.
Morales-Martinez A, Sanchez-Mendoza A, Martinez-Lazcano J, Pineda-Farias J, Montes S, El-Hafidi M . Essential fatty acid-rich diets protect against striatal oxidative damage induced by quinolinic acid in rats. Nutr Neurosci. 2016; 20(7):388-395. DOI: 10.1080/1028415X.2016.1147683. View

5.
Sanberg P, Calderon S, Giordano M, Tew J, Norman A . The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp Neurol. 1989; 105(1):45-53. DOI: 10.1016/0014-4886(89)90170-2. View